On April 2, 2026, President Trump signed an executive order imposing a 100% tariff on patented pharmaceutical products and their ingredients, invoking Section 232 of the Trade Expansion Act of 1962 on national security grounds. The order came with extensive carveouts and compliance pathways that made the headline figure largely aspirational — but established the framework for weaponizing drug pricing as a trade negotiation tool.
Legal Authority
The administration used Section 232 rather than IEEPA (International Emergency Economic Powers Act), which the Supreme Court struck down as a tariff authority in February 2026 in a 6-3 ruling. Section 232, which allows tariffs when imports threaten national security, had been upheld by courts for steel and aluminum tariffs and provided a more legally defensible path.
Structure and Exemptions
The 100% rate applied as a ceiling, with multiple off-ramps:
Significance
The structure revealed the order's true purpose: not to impose 100% tariffs, but to create coercive leverage over pharmaceutical companies to sign pricing and manufacturing agreements with the administration. The MFN pricing provision — requiring companies to charge the U.S. the lowest price offered to any other country — was a version of the drug pricing negotiation authority that Congress had been unable to pass legislatively.
The use of Section 232 after the SCOTUS IEEPA defeat demonstrated the administration's pattern of cycling through legal authorities when courts blocked one pathway. The February Section 122 pivot and now the Section 232 pharmaceutical tariffs showed a systematic strategy of legal authority shopping to maintain executive tariff power.